Regulatory antibody strategy vs. allergies

Allergene Inc., which is developing regulatory antibodies to treat allergic diseases, told BioCentury that it is looking to raise a second venture round of about $5 million from either venture capital or private investors.

Allergene is about 18 months away from the clinic with antibodies to poison ivy/oak and grasses. The company is developing chimeric versions of antibodies it has tested in animals.